Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953. doi:10.1002/ijc.3193730350310
   PubMed Web of Science ®Google Scholar
• Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015;64(3):381–387. doi:10.1136/gutjnl-2014-30812425320104
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Li M, Wan X, Wang Y, Sun Y, Yang G, Wang L. Time trends of esophageal and gastric cancer mortality in China, 1991–2009: an age-period-cohort analysis. Sci Rep. 2017;7(1):6797. doi:10.1038/s41598-017-07071-528754910
   PubMed Web of Science ®Google Scholar
• Drahos J, Wu M, Anderson WF, et al. Regional variations in esophageal cancer rates by census region in the United States, 1999–2008. PLoS One. 2013;8(7):e67913. doi:10.1371/journal.pone.006791323861830
   PubMed Web of Science ®Google Scholar
• Lordick F, Mariette C, Haustermans K, Obermannova R, Arnold D. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v50–v57. doi:10.1093/annonc/mdw32927664261
   PubMed Web of Science ®Google Scholar
• Stahl M, Mariette C, Haustermans K, Cervantes A, Arnold D. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi51–vi56. doi:10.1093/annonc/mdt34224078662
   PubMed Web of Science ®Google Scholar
• Thallinger CM, Raderer M, Hejna M. Esophageal cancer: a critical evaluation of systemic second-line therapy. J Clin Oncol. 2011;29(35):4709–4714. doi:10.1200/JCO.2011.36.759922067408
   PubMed Web of Science ®Google Scholar
• Song Z, Zhang Y. Second-line docetaxel-based chemotherapy after failure of fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinoma. Onco Targets Ther. 2014;7:1875–1881.25342911
   PubMed Web of Science ®Google Scholar
• Burkart C, Bokemeyer C, Klump B, Pereira P, Teichmann R, Hartmann JT. A Phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer. Anticancer Res. 2007;27(4C):2845–2848.17695458
   PubMed Web of Science ®Google Scholar
• Mizota A, Shitara K, Kondo C, et al. A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy. Oncology. 2011;81(3–4):237–242. doi:10.1159/00033405722094594
   PubMed Web of Science ®Google Scholar
• Albertsson M, Johansson B, Friesland S, et al. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. Med Oncol. 2007;24(4):407–412. doi:10.1007/s12032-007-0028-617917090
   PubMed Web of Science ®Google Scholar
• Shirakawa T, Kato K, Nagashima K, et al. A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy. Cancer Chemother Pharmacol. 2014;74(6):1207–1215. doi:10.1007/s00280-014-2597-325267597
   PubMed Web of Science ®Google Scholar
• Grunberger B, Raderer M, Schmidinger M, Hejna M. Palliative chemotherapy for recurrent and metastatic esophageal cancer. Anticancer Res. 2007;27(4C):2705–2714.17695436
   PubMed Web of Science ®Google Scholar
• Tartari F, Santoni M, Burattini L, Mazzanti P, Onofri A, Berardi R. Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: recent insights and future challenges. Cancer Treat Rev. 2016;48:20–24. doi:10.1016/j.ctrv.2016.06.00227310708
   PubMed Web of Science ®Google Scholar
• Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, Phase 3 study. Lancet Oncol. 2020;21(6):832–842. doi:10.1016/S1470-2045(20)30110-832416073
   PubMed Web of Science ®Google Scholar
• Insinga RP, Vanness DJ, Feliciano JL, Vandormael K, Traore S, Burke T. Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US. J Med Econ. 2018;21(12):1191–1205. doi:10.1080/13696998.2018.152141630188231
   PubMed Web of Science ®Google Scholar
• Chouaid C, Bensimon L, Clay E, et al. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France. Lung Cancer. 2019;127:44–52. doi:10.1016/j.lungcan.2018.11.00830642550
   PubMed Web of Science ®Google Scholar
• Health NIo. Common terminology criteria for adverse events (CTCAE) version 4.03; 2010. Available from: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed June, 15, 2021.
   Google Scholar
• Liu YJ, Zhu GP, Guan XY. Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma. Oral Oncol. 2012;48(6):554–559. doi:10.1016/j.oraloncology.2012.01.00422289637
   PubMed Web of Science ®Google Scholar
• Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 2021;112(1):90–92. doi:10.1016/j.ad.2019.05.00932891586
   PubMed Web of Science ®Google Scholar
• Wong IO, Kuntz KM, Cowling BJ, Lam CL, Leung GM. Cost effectiveness of mammography screening for Chinese women. Cancer. 2007;110(4):885–895. doi:10.1002/cncr.2284817607668
   PubMed Web of Science ®Google Scholar
• The Supreme People’s Court of The People’s Republic of China. The Supreme People’s Court on some issues concerning the application of law to the trial of cases of compensation for personal injury; 2017. Available from: http://www.court.gov.cn/fabu-xiangqing-73512.html. Accessed June 15, 2021.
   Google Scholar
• Fayers PM, Bjordal K, Groenvold M, Curran D, Bottomley A. The EORTC QLQ-C30 Scoring, Manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer; 2001.
   Google Scholar
• van Kleef JJ, Ter Veer E, van den Boorn HG, et al. Quality of life during palliative systemic therapy for esophagogastric cancer: systematic review and meta-analysis. J Natl Cancer Inst. 2020;112(1):12–29.31251346
   PubMedGoogle Scholar
• Janmaat VT, Bruno MJ, Polinder S, et al. Cost-effectiveness of cetuximab for advanced esophageal squamous cell carcinoma. PLoS One. 2016;11(4):e0153943. doi:10.1371/journal.pone.015394327100871
   PubMed Web of Science ®Google Scholar
• Nyman JA. Cost recommendations in the second edition of cost-effectiveness in health and medicine: a review. MDM Policy Pract. 2018;3(1):2381468318765162.30288440
   PubMedGoogle Scholar
• Dieleman JL, Campbell M, Chapin A, et al. Future and potential spending on health 2015–40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. Lancet. 2017;389(10083):2005–2030. doi:10.1016/S0140-6736(17)30873-528433260
   PubMed Web of Science ®Google Scholar
• Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506–1517. doi:10.1016/S1470-2045(19)30626-631582355
   PubMed Web of Science ®Google Scholar
• Kojima T, Shah MA, Muro K, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38(35):4138–4148. doi:10.1200/JCO.20.0188833026938
   PubMed Web of Science ®Google Scholar
• Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9(3):235–251. doi:10.1002/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O10790702
   PubMed Web of Science ®Google Scholar
• Zhang PF, Xie D, Li Q. Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma. Future Oncol. 2020;16(17):1189–1198. doi:10.2217/fon-2019-082132407173
   PubMed Web of Science ®Google Scholar